Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
News|Articles|February 2, 2005
- Pharmaceutical Technology-02-02-2005
- Volume 29
- Issue 2
Emerging Analytical Technology: Moving from the Lab to the Line
Analytical instrument suppliers are developing manufacturing-tailored tools that are small, precise, and easy to use.
Advertisement
Articles in this issue
almost 22 years ago
Correcting the Coursealmost 22 years ago
February 2005almost 22 years ago
Good Work and True: USP Prepares for Convention 2005almost 22 years ago
Contract Manufacturers Getting Squeezedalmost 22 years ago
In the Spotlight-February 2005almost 22 years ago
Drug Safety Fears May Limit Reimporting and Shape R&Dalmost 22 years ago
In Defense of USP Singlet TestingAdvertisement
Related to this article
Clinical, manufacturing, safety, and commercial teams all lean on shared data. They need to agree on who publishes each data product, who can use it, and what evidence goes with it.
Continuous overall equipment effectiveness can be used to pinpoint hidden downtime and process bottlenecks in real time.
Subathra Ramamoorthy, Veranova, on how forced degradation and trace impurity profiling in potent APIs shape regulator-ready analytical methods.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
2
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
3
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
4
1074 Revision Needs Formulator Feedback: AAPS PharmSci 360 2026
5